Red Queen Bio
Red Queen Bio is an AI biosecurity Public Benefit Corporation that maps AI-enabled biological threats alongside frontier AI labs and designs pre-built medical countermeasures using AI-driven pipelines, serving governments, AI labs, and biopharma.
- Company typePrivate
- Founded2025
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Red Queen Bio does
Red Queen Bio is an AI biosecurity company founded in November 2025 in Boston, Massachusetts, and structured as a Public Benefit Corporation. The company was spun out by Nikolai Eroshenko and Hannu — co-founders of clinical-stage mRNA company HelixNano — after observing that frontier AI models exhibit biological creativity that cuts both ways: capable of designing breakthrough therapies, but also of conceiving novel biothreats. Red Queen Bio's stated mission is to scale biological defenses at the same rate that AI capabilities in biology advance, a thesis it calls 'defensive co-scaling.'
The company's technology stack comprises three integrated components: a Biothreat Mapping Platform that works with frontier AI labs to identify AI-enabled biological threats; a Countermeasure Design Pipeline built on frontier AI models, lab automation, and reinforcement learning, engineered to scale directly with compute; and On-Demand Biologics Manufacturing to produce identified countermeasures rapidly. A documented demonstration of the pipeline's capability is a collaboration with OpenAI in which GPT-5 autonomously iterated on molecular cloning protocols to achieve a 79-fold improvement in cloning efficiency through a novel mechanism combining RecA recombinase and phage T4 gp32 proteins. The company is committed to open collaboration with all AI labs, biopharma firms, and governments globally.
The business model is still emerging. Revenue streams are described conceptually as biosecurity countermeasure services (likely government contracts and biopharma collaborations), a financial co-scaling model drawing on catastrophic risk insurance frameworks, and collaborative research grants. Go-to-market is enterprise field sales targeting frontier AI labs, US and international governments, and biopharma companies, supplemented by policy engagement to create private-sector biosecurity investment incentives. The company closed a $15M seed round in November 2025 led by OpenAI, with participation from Cerberus Ventures, Fifty Years, and Halcyon Futures. No pricing, recurring revenue, or commercial contracts have been disclosed, and the company is pre-commercial at launch.
Red Queen Bio firmographics
Firmographics- Name
- Red Queen Bio
- Legal name
- Red Queen Bio
- Website
- https://redqueen.bio
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Red Queen Bio is an AI biosecurity Public Benefit Corporation that maps AI-enabled biological threats alongside frontier AI labs and designs pre-built medical countermeasures using AI-driven pipelines, serving governments, AI labs, and biopharma.
- Ownership category
- akta.pro rank
Red Queen Bio industry classification
Industry- Product category
- AI Biosecurity
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
- akta.pro secondary industries
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Biothreat/Biocontainment & Select Agent Public Health Laboratories (HLAJAIAL), Liquid Handling & Laboratory Automation (Pipettes, Robots, Workstations) (HLAGAIAD)
Keywords
Where Red Queen Bio is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Red Queen Bio business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Biosecurity Countermeasure Services: The company designs and develops medical countermeasures against AI-enabled biothreats, likely through government contracts, research collaborations with AI labs and biopharma, and potentially through licensing arrangements with manufacturers.
- Financial Co-Scaling Model: Exploring catastrophic risk insurance frameworks and other safety-critical industry financial models to create sustainable revenue. Governments with flat biodefense budgets cannot solve the problem alone, so the company seeks private-sector capital incentives to co-fund biosecurity infrastructure.
- Collaborative Research Grants: Engagement with policymakers in the US and abroad to create incentives for private-sector biosecurity investment, potentially including government grants and public-private partnerships.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels2 records
Red Queen Bio product offering
Product offeringCore offering
Red Queen Bio designs and develops AI-driven biodefense capabilities that map AI-enabled biological threats and pre-build medical countermeasures. Its countermeasure design pipeline is built on frontier AI models, lab automation, and reinforcement learning, and is engineered to scale directly with compute, paired with on-demand biologics manufacturing for rapid production.
Product overview
Red Queen Bio operates as a unified AI biosecurity platform with three integrated core components: the Biothreat Mapping Platform works with frontier AI labs to identify and map AI-enabled biological threats; the Countermeasure Design Pipeline leverages leading AI models, lab automation, and reinforcement learning to design medical countermeasures; and On-Demand Biologics Manufacturing enables rapid production of these countermeasures. This integrated stack provides the technological foundation for 'defensive co-scaling'—coupling defensive compute and funding to the same technological and financial forces driving the AI capability race.
Differentiator
Problem solved
Functional benefit
Products and services
- Biothreat Mapping Platform Scalable platform that works with frontier AI labs to identify and map biological threats enabled by advanced AI capabilities, providing threat intelligence for defensive preparedness. It is intended for AI labs, biopharma companies, and government biosecurity agencies.
- Countermeasure Design Pipeline AI-driven pipeline built on frontier models, lab automation, and reinforcement learning to pre-build medical countermeasures against identified biothreats, engineered to scale directly with compute resources. It is intended for AI labs, biopharma partners, and government biodefense agencies.
- On-Demand Biologics Manufacturing Manufacturing capability for producing biological countermeasures on-demand, integrated with the countermeasure design pipeline to enable rapid response to emerging threats. It is intended for biopharma collaborators and government biodefense customers.
Quantifiable outcome
- 79x improvement in cloning efficiency achieved in a wet lab collaboration with OpenAI using GPT-5, through a novel mechanism combining RecA recombinase and phage T4 gp32 proteins
- +1 more outcomes
Companies that use Red Queen Bio
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Red Queen Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature4 records
Red Queen Bio partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights6 records
Red Queen Bio competitors and assessment
Company assessmentEmerging players
- Insitro: Insitro applies ML and high-throughput biology to drug discovery, overlapping with Red Queen Bio's AI + lab automation + biologic countermeasure design stack. It is a relevant emerging player but focuses on therapeutic discovery rather than biosecurity.
- Cradle Bio: Cradle uses AI for protein design and engineering, comparable to Red Queen Bio's AI-driven biologic countermeasure design capabilities. It overlaps in the AI-for-biologics category but focuses on commercial protein engineering applications.
- Lumen Bioscience: Lumen Bioscience develops orally delivered biologic therapeutics and countermeasure candidates. It overlaps with Red Queen Bio in biologic countermeasure development and on-demand manufacturing, though with a more traditional discovery approach.
- Profluent Bio: Profluent develops AI foundation models for protein design, directly comparable to Red Queen Bio's use of frontier AI models for biological design. It represents an emerging AI-biologics peer with overlapping core methodology.
- EvolutionaryScale: EvolutionaryScale builds frontier AI foundation models for biology. It is comparable in developing large-scale AI models for biological applications and could serve as either a partner or competitor to Red Queen Bio's frontier-model-based pipeline.
Broad incumbents
- Ginkgo Bioworks: Ginkgo Bioworks is a large, established synthetic biology platform with explicit biodefense programs. It overlaps with Red Queen Bio in countermeasure-relevant biologics engineering and government biodefense contracting, but operates at much broader scope.
- Recursion Pharmaceuticals: Recursion uses AI/ML and lab automation for drug discovery at scale. It is comparable to Red Queen Bio in the AI-driven biologic discovery architecture (frontier models + wet lab + reinforcement learning), though focused on therapeutics rather than biosecurity.
Direct peers
- Valthos: Valthos is a biosecurity-focused company also backed by OpenAI, targeting AI-related biological risks. It is the closest direct competitor to Red Queen Bio in the emerging AI biosecurity category, with overlapping mission and investor base.
- HelixNano: HelixNano is the clinical-stage mRNA company co-founded by Red Queen Bio's founders (Nikolai and Hannu). It is directly comparable in therapeutic modality (mRNA biologics) and represents the technical foundation from which Red Queen Bio spun out.
Others
- National Resilience: Resilience is a biomanufacturing company focused on biologics production at scale. It is comparable to Red Queen Bio's on-demand biologics manufacturing component and could serve as a manufacturing partner or capacity provider.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Red Queen Bio social profiles
Digital presenceRed Queen Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Red Queen Bio leadership team
Management profileNumber of profiles
Profiles2 records
Red Queen Bio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Red Queen Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Red Queen Bio
What does Red Queen Bio do?
Red Queen Bio designs and develops AI-driven biodefense capabilities that map AI-enabled biological threats and pre-build medical countermeasures. Its countermeasure design pipeline is built on frontier AI models, lab automation, and reinforcement learning, and is engineered to scale directly with compute, paired with on-demand biologics manufacturing for rapid production.
Is Red Queen Bio a public or private company?
Red Queen Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Red Queen Bio founded?
Red Queen Bio was founded in 2025. It employs 11 to 50 people.
Where is Red Queen Bio based?
Red Queen Bio is headquartered in Boston, United States, in the North America region.
How does Red Queen Bio make money?
Three revenue lines are on record. Biosecurity Countermeasure Services are the primary driver. The others are financial Co-Scaling Model and collaborative Research Grants.
Who are Red Queen Bio's main competitors?
Emerging players on record are Insitro, Cradle Bio, Lumen Bioscience, Profluent Bio and EvolutionaryScale. Broad incumbents are Ginkgo Bioworks and Recursion Pharmaceuticals. Direct peers are Valthos and HelixNano. National Resilience is listed as an others.
Does Red Queen Bio have an API?
No public API is recorded for Red Queen Bio.
What industry is Red Queen Bio in?
Red Queen Bio's product category is AI Biosecurity. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 2836.